GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

GSK plc GSK announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep ...

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for ...

The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

Meanwhile, GSK finds itself in a curious position with Blenrep. Back in November 2022, GSK pulled Blenrep from the U.S. market a little more than two weeks after the ADC had failed to top a ...

GSK’sGSK-3.16 % decrease; red down pointing triangle blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return ...

The Blenrep results presented Monday are from a Phase 3 test, DREAMM-7, that enrolled nearly 500 patients whose multiple myeloma relapsed or was refractory to at least one earlier line of therapy.

GSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late ...

Blenrep won accelerated FDA approval in 2020 as a fifth-line multiple myeloma treatment, making it the first-approved BCMA-targeting therapy. In 2022, GSK reported that Blenrep failed to meet the ...